1-Propylpiperidine-3-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-Propylpiperidine-3-carboxamide
• 化学式: C₉H₁₈N₂O
• mdl: MFCD05857029
• 分子量: 170.25
• InChiKey: UYRCHWMOBMMMGD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.888
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• INHIBITORS OF HIV REPLICATION
  申请人：STURINO Claudio

  公开号：US20100261714A1

  公开（公告）日：2010-10-14

  Compounds of formula (I): wherein R 1 , R 2 , A 1 , A 2 , A 3 , A 4 , X and Y are as defined herein, are useful as inhibitors of HIV replication.

  式(I)的化合物： 其中R1、R2、A1、A2、A3、A4、X和Y如本文所定义，可用作HIV复制抑制剂。
• [EN] ESTER SUBSTITUTED ION CHANNEL BLOCKERS AND METHODS FOR USE<br/>[FR] BLOQUEURS DE CANAUX IONIQUES SUBSTITUÉS PAR UN ESTER ET MÉTHODES D'UTILISATION
  申请人：NOCION THERAPEUTICS INC

  公开号：WO2020185915A1

  公开（公告）日：2020-09-17

  The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof. The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, itch, and neurogenic inflammation.

  本发明提供了式（I）的化合物，或其药学上可接受的盐。该发明的化合物、组合物、方法和试剂盒对于治疗疼痛、瘙痒和神经源性炎症是有用的。
• [EN] COMPOUNDS FOR USE IN STABILISING p53 MUTANTS<br/>[FR] COMPOSÉS PERMETTANT DE STABILISER LES MUTANTS DE P53
  申请人：MEDICAL RES COUNCIL

  公开号：WO2012175962A1

  公开（公告）日：2012-12-27

  Provided are compounds for use in a method of treatment of a subject who has a lesion or a tumour in which p53 carries a Y220C mutation, in which the compound is selected from compounds of the following formula (I), and pharmaceutically acceptable salts, hydrates, and solvates thereof: (I) R: where A is CR4 or N; -R-1 is selected from -OH, -OMe, -NH2, -SH, -F and -CF3; -R2 is selected from -CI, -Br, -I, and ethynyl (-C≡CH); -R3 is selected from -I, -Br, -CI, ethynyl (-C≡CH), -R35, -H, -OMe, and -N02; wherein -R3S is selected from: and -R5 is selected from -COOH and: 8A formula Ilia formula 1Mb formula 111 o 3 where -R6, -R7A, - R7B, -Rs, and -R8A are as defined in the specification. Compounds of formula (I) are also provided, as is their use in methods of treatment, and methods for their preparation.

  提供了用于治疗患有p53携带Y220C突变的病变或肿瘤的方法中使用的化合物，其中该化合物从以下公式(I)的化合物中选择，并且其药学上可接受的盐、水合物和溶剂化合物：(I) R：其中A为CR4或N；-R-1选择自-OH、-OMe、-NH2、-SH、-F和-CF3；-R2选择自-Cl、-Br、-I和乙炔（-C≡CH）；-R3选择自-I、-Br、-Cl、乙炔（-C≡CH）、-R35、-H、-OMe和-N02；其中-R3S选择自：和-R5选择自-COOH和：8A公式Ilia公式1Mb公式111 o 3其中-R6、-R7A、-R7B、-Rs和-R8A如规范中所定义。还提供了公式(I)的化合物，以及它们在治疗方法中的使用和制备方法。
• Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors
  申请人：Molteni Valentina

  公开号：US20070149538A1

  公开（公告）日：2007-06-28

  Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.

  本文描述了包含二芳胺结构特征的化合物。还描述了制备这种化合物的方法，使用这种化合物调节c-kit受体活性的方法，以及包含这种化合物的药物组合物和药物。本文还描述了使用这种化合物、药物组合物和药物治疗和/或预防和/或抑制和/或改善与c-kit受体活性相关的病理学和/或症状学疾病或状况的方法。
• DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS
  申请人：Molteni Valentina

  公开号：US20090264649A1

  公开（公告）日：2009-10-22

  Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.

  本文描述了一些包括二芳基胺结构特征的化合物。还描述了制备这些化合物的方法，利用这些化合物调节c-kit受体活性的方法，以及包含这些化合物的药物组合物和药物。本文还描述了使用这些化合物、药物组合物和药物来治疗和/或预防和/或抑制和/或改善与c-kit受体活性相关的疾病或症状的方法。